in Health care
Sandoz gets European Commission nod for Hyrimoz high-concentration formulation
Basel: Sandoz has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for a citrate-free high concentration formulation (HCF; 100 mg/mL) of its biosimilar Hyrimoz (adalimumab). The approval includes all indications covered by the reference medicine*: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. “Living […] More
